1. Ahnen, D. J., Feigl, P., Quan, G., Feneoglio-Preiser, C., Lovata, L. C., Bunn, P. A., Stemmerman, G., Wells, J. D., Macdonald, J. S., & Meyskens, Jr., F. L. (1998). Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Research, 58, 1149-1158.
2. Baguley, B. C. (2010). Multidrug resistance in cancer. Methods Molecular Biology 596, 1-14.
https://doi.org/10.1007/978-1-60761-416-6_1
3. Bahrami, A., Amerizadeh, F., Hassanian, S., M., ShahidSales, S., Khazaei, M., Maftauh, M., Ghayour-Mobarhan, M., Ferns, G. A., & Avan, A. (2018). Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin‐based chemotherapy. Journal of Cellular Physiology, 233(3), 2193-2201. https://doi.org/10.1002/jcp.25966
4. Cancer Today [Internet]. (2021), [cited 2021 Jun 30]. Available from: https://gco.iarc.fr/today/fact-sheets-cancers
5. Chao, C. C., Huang, Y. T., Ma, C. M., Chou, W. Y., & Lin-Chao, S. (1992). Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line. Molecular Pharmacology, 41(1), 69-75.